ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Drug toxicity"

  • Abstract Number: L08 • ACR Convergence 2020

    Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)

    Thomas MacDonald1, Isla Mackenzie1, George Nuki2 and Ian Ford3, 1University of Dundee, Dundee, Scotland, United Kingdom, 2University of Edinburgh, Edinburgh, Scotland, United Kingdom, 3University of Glasgow, Glasgow, Scotland, United Kingdom

    Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
  • Abstract Number: 0952 • ACR Convergence 2020

    Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

    Puja Khanna1, Dinesh Khanna1, Gary Cutter2, Jeffrey Foster2, Joshua Melnick3, Sara Jaafar1, Stephanie Biggers2, AKM Rahman2, Hui-Chen Kuo2, Michelle Feese2 and Kenneth Saag4, 1University of Michigan, Ann Arbor, MI, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham (UAB), Vestavia Hills, AL, 4University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: Pegloticase, a recombinant, pegylated uricase, is used for treatment of gout in patients who fail oral urate lowering therapy (ULT). Despite successful reduction of…
  • Abstract Number: 1844 • ACR Convergence 2020

    Hydroxychloroquine and QTc Prolongation in a Cohort of SLE Patients

    Mayce Haj-Ali1 and H. Michael Belmont2, 1NYU Langone Health, new york, 2NYU School of Medicine, New York, NY

    Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). Cardiac toxicity is very rare in SLE, but has…
  • Abstract Number: 1015 • ACR Convergence 2020

    The Prevalence and Risk Factors for Liver Fibrosis Among Rheumatoid Arthritis (RA) Patients on Disease-Modifying Anti-rheumatic Drugs (DMARDs)

    Chou Luan Tan1, Boon Han Ng2, Noor Shahrazat Ahmad2, Shahrul Aiman Soelar2, Muhammad Zulhilmi Asyraf Jazlan2, Mohd Ammar Dzakirin Md Mansor2, Mohd Azri Mohd Suan2, Kuang Kiat Kiew2, Zalwani Zainuddin2, Muhammad Radzi Abu Hassan2 and Chong Hong Lim2, 1Hospital Sultanah Bahiyah, Kementerian Kesihatan Malaysia, Alor Setar, Kedah, Malaysia, 2Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia

    Background/Purpose: Majority of DMARDs, including methotrexate (MTX), leflunomide (LEF) and sulfasalazine (SSZ) arebelieved to be hepatotoxic, causing liver fibrosis. However, the clinical findings were inconsistent.…
  • Abstract Number: 1846 • ACR Convergence 2020

    Evaluating the Risk of QT-prolongation Associated with Hydroxychloroquine Use with and Without Antidepressants in SLE Patients with Fibromyalgia

    Jacinta Renaldi1, Fotios Koumpouras1 and Mei Xue Dong1, 1YALE SCHOOL OF MEDICINE, New Haven, CT

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease predominantly affecting woman of child-bearing age. Concurrent fibromyalgia syndrome (FMS) has been reported in…
  • Abstract Number: 1360 • ACR Convergence 2020

    New-Onset Inflammatory Bowel Diseases Among IL-17 Inhibitors-Treated Patients: Results from the Case-Control MISSIL Study

    Jean-Guillaume Letarouilly1, Benjamin Pariente2, Thao Pham3, Emilie Acquacalda4, Béatrice Banneville5, Sébastien Barbarot6, Elodie Bauer7, Pauline Baudart8, Pascal Claudepierre9, Arnaud Constantin10, Emmanuelle Dernis11, Renaud Felten12, Philippe Gaudin13, Céline Girard14, Bruno Gombert15, Philippe Goupille16, Xavier Guennoc17, Isabelle Henry-Desailly18, Denis Jullien19, Elena Karimova20, Sylvain Lanot21, Loïc Le Dantec22, Tristan Pascart23, Laurianne Plastaras24, Nathalie Sultan-Bichat25, Xavier Truchet26, Stéphane Varin27, Daniel Wendling28, Lousie Gaboriau29, Delphine Staumont-Sallé30, Laurent Peyrin-Biroulet31 and René-Marc Flipo1, 1Univ-Lille, CHU Lille, department of rheumatology, Lille, France, 2Univ-Lille, CHU Lille, department of gastroenterology, Lille, France, 3Aix Marseille Univ, APHM, department of rheumatology, Marseille, France, 4CHPG, department of rheumatology, Monaco, Monaco, 5AP-HP, Hôpital Pitié-Salpêtrière, Service de Rhumatologie, Paris, 75013, Paris, France, 6CHU de Nantes, department of dermatology, Nantes, France, 7CHRU Nancy, department of rheumatology, VANDOEUVRE LES NANCY, Lorraine, France, 8CHU Caen, department of rheumatology, Caen, France, 9Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, 10Hospital Pierre Paul Riquet, Toulouse, France, 11CH Le Mans, department of rheumatology, Le Mans, France, 12Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, 13CHU Grenoble, department of rheumatology, Grenoble, France, 14CHU Montpellier, department of rheumatology, Montpellier, France, 15CH La Rochelle, department of rheumatology, La Rochelle, France, 16CHU Tours, department of rheumatology, Tours, France, 17CH Saint-Brieuc, department of rheumatology, Saint-Brieuc, France, 18CHU Amiens, department of rheumatology, Amiens, France, 19CHU Lyon, department of dermatology, Lyon, France, 20CH Lens, department of dermatology, Lens, France, 21CH Alençon, department of rheumatology, Alençon, France, 22Ahnac, department of rheumatology, Hénin-Beaumont, France, 23Ghicl, Hôpital Saint-Philibert, department of rheumatology, Lomme, France, 24CH Colmar, department of gastroenterology, Colmar, France, 25CH Ouest-Réunion, department of dermatology, Saint Paul, La Réunion, France, 26HIA Sainte-Anne, department of gastroenterology, Toulon, France, 27CHD Vendée, department of rheumatology, La Roche-sur-Yon, France, 28CHU Besançon, department of rheumatology, Besancon, France, 29Univ-Lille, CHU Lille, department of pharmacovigilance, Lille, France, 30Univ-Lille, CHU Lille, department of dermatology, Lille, France, 31CHU Nancy, department of gastroenterology, VANDOEUVRE LES NANCY, Lorraine, France

    Background/Purpose: A warning regarding safety of Interleukin 17 inhibitors (IL-17i) has been issued from data of randomized controlled trials (RCT) showing cases of new-onset inflammatory bowel…
  • Abstract Number: 2001 • ACR Convergence 2020

    Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial

    Kathleen Vanni1, Nancy Berliner1, Nina Paynter2, Robert Glynn2, Jean MacFadyen1, Joshua Colls1, Fengxin Lu1, Chang Xu2, Paul Ridker1 and Daniel H Solomon1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston

    Background/Purpose: Low dose methotrexate (LD-MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia and leukopenia, but…
  • Abstract Number: 1494 • ACR Convergence 2020

    Patient-Reported Adverse Events, Quality of Life and Treatment Adherence in Juvenile Idiopathic Arthritis: Analysis of Two Large International Cohorts

    Alessandra Alongi1, Maria Trachana2, Valda Stanevicha3, Laura Marinela Ailioaie4, Elena Tsitsami5, Angelo Ravelli6, Alessandro Consolaro6 and Nicolino Ruperto7, 1IRCCS Istituto Giannina Gaslini, Genoa, Italy, 2Aristotle University of Thessaloniki, Thessaloníki, Greece, 3Riga Stradins University, Riga, Latvia, 4Alexandru Ioan Cuza University of Iasi, Iasi, Romania, 5Aghia Sophia Childrens Hospital, Athens, Greece, 6Università degli Studi di Genova, Genoa, Italy, 7Istituto Giannina Gaslini, Genova, Italy

    Background/Purpose: Juvenile idiopathic arthritis (JIA) patients may experience significant medication-related adverse effects (AEs), which may adversely affect health-related quality of life (HRQOL), daily activities and…
  • Abstract Number: 1573 • ACR Convergence 2020

    Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors

    Kevin Lee1, Carrie Ye2 and Shokrollah Elahi3, 1Internal Medicine, University of Alberta, Edmonton, AB, Canada, 2Rheumatology, University of Alberta, Edmonton, AB, Canada, 3Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…
  • Abstract Number: 1576 • ACR Convergence 2020

    Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review

    Adam Kilian1, Yu Pei Eugenia Chock2, Irvin Huang3, Elizabeth Graef4, Laura Upton5, Aneka Khilnani6, Sonia Silinsky Krupnikova7, Ibrahim Almaghlouth8, Laura Cappelli9, Ruth Fernandez-Ruiz10, Brittany Frankel3, Jourdan Frankovich11, Carly Harrison12, Bharat Kumar13, Kanika Monga14, Jorge Rosario Vega11, Namrata Singh15, Jeffrey Sparks16, Elaine Sullo6, Kristen Young17, Ali Duarte-Garcia18, Michael Putman19, Sindhu Johnson20, Jean Liew3 and Aruni Jayatilleke21, 1George Washington University, Washington, DC, 2Yale School of Medicine, Greenwich, CT, 3University of Washington, Seattle, WA, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Georgetown University School of Medicine, Washington, DC, 6The George Washington University School of Medicine and Health Sciences, Washington, DC, 7The George Washington University School of Medicine and Health Sciences, Rockville, MD, 8King Saud University, Riyadh, Saudi Arabia, 9Johns Hopkins School of Medicine, Baltimore, MD, 10New York University School of Medicine, New York, 11Temple University, Philadelphia, PA, 12Lupus Chat, NA, 13University of Iowa Hospitals and Clinics, Iowa City, IA, 14UT Health Rheumatology, HOUSTON, TX, 15University of Washington, Bellevue, WA, 16Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 17University of Texas Southwestern Medical Center, Dallas, TX, 18Mayo Clinic, Rochester, MN, 19Northwestern University, Chicago, IL, 20University of Toronto, Toronto, ON, Canada, 21Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

    Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
  • Abstract Number: 1579 • ACR Convergence 2020

    Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response

    Pankti Reid1, Daniel Olson2 and Thomas Gajewski2, 1University of Chicago, Chicago, IL, 2University of Chicago Medical Center, Department of Medicine, Section of Hematology Oncology, Chicago

    Background/Purpose: High grade immune-related adverse events (irAEs) to cancer immune checkpoint inhibitors (ICI) require considerable immunosuppression (IS) with high-dose steroids and steroid-sparing IS (SSIS) for…
  • Abstract Number: 1580 • ACR Convergence 2020

    Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events

    David Liew1, Aurora Poon2, Christopher McMaster3, Claire Owen4, Jessica Leung5, Albert Frauman2, Jonathan Cebon6, Andrew Scott6 and Russell Buchanan7, 1Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia, 2Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, 3Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, 4Austin Health, Melbourne, Victoria, Australia, Ashburton, Victoria, Australia, 5Austin Health, Melbourne, Victoria, Australia, Melbourne, 6Austin Health, Melbourne, Victoria, Australia, Melbourne, Australia, 7Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia

    Background/Purpose: The pathogenesis of rheumatic immune-related adverse events (irAEs) from checkpoint inhibitor cancer immunotherapy directed against programmed cell death protein 1 (PD-1) and programmed death…
  • Abstract Number: 1581 • ACR Convergence 2020

    Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review

    Michael Cunningham1, Carolina Alvarez2, Shruti Saxena Beem3, Todd Schwartz4 and Rumey Ishizawar5, 1UNC Hospitals, Durham, NC, 2University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, 3University of North Carolina at Chapel Hill, Chapel Hill, 4University of North Carolina-Chapel Hill, Chapel Hill, NC, 5University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Immune checkpoint inhibitors (ICIs) target checkpoint proteins PD-1/PD-L1 and CTLA-4 to activate and enhance the cytotoxic effects of T lymphocytes against tumor cells [1-2].…
  • Abstract Number: 1594 • ACR Convergence 2020

    Hydroxychloroquine Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution

    Rebecca Overbury1, Jakrapun Pupaibool2, Christopher Hansen2 and Dorota Lebiedz-Odrobina2, 1University of Utah and Primary Children's Hospital, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT

    Background/Purpose: One rare but devastating adverse event related to the use of hydroxychloroquine (HCQ) is retinal toxicity. Retinal toxicity rates from HCQ can be as…
  • Abstract Number: 0009 • ACR Convergence 2020

    Prevalence of Hydroxychloroquine and Chloroquine Side Effects in Rheumatology Patients: A Retrospective Survey of 115 Cases

    Zakaria El Ouali1, Elie Bassa1, Abdoul-Rahamane Halidou Idrissa1, Sarah Tazi1, Samy Housbane2, Mohamed Bennani Othmani2, Kawtar Nassar1 and Saadia Janani1, 1Department of Rheumatology, University Hospital of Ibn Rochd, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco, 2Medical Informatics Laboratory, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco, Casablanca, Grand Casablanca, Morocco

    Background/Purpose: Antimalarial drugs (ADs), including chloroquine (CQ) and hydroxychloroquine (HCQ), have anti-inflammatory, immunomodulatory, antiparasitic, anti-thrombotic, and antiviral properties. Their indications in rheumatology have been known…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.